ReviewJournal of the International Association of Providers of AIDS Care
Lenacapavir for HIV Prevention in Africa: Opportunities, Barriers, and Policy Priorities.
Review in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite global progress in HIV prevention, Africa continues to carry a disproportionate share of the epidemic and its related inequalities. Daily oral pre-exposure prophylaxis (PrEP) has been limited by adherence and accessibility challenges. Lenacapavir, a long-acting injectable PrEP administered every six months, has shown efficacy in clinical trials among high-risk populations in sub-Saharan Africa and offers new promise for prevention efforts. This Policy Perspective examines the opportunities and barriers to equitable access and rollout of lenacapavir in African settings. Key challenges include high implementation costs, limited health infrastructure, regulatory delays, supply chain constraints, and social barriers such as stigma, misinformation, and mistrust. We argue that the promise of lenacapavir will only be realized if its introduction is accompanied by policies and programs that address these systemic obstacles. Ensuring equitable access will require robust stakeholder collaboration, meaningful community engagement, and deliberate efforts to strengthen health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.